

Abemaciclib monarchE


PRELIMINARY SCORE

CURATIVE



Scoring of iDFS on the same basis as DFS

NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Abemaciclib monarchE

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of adult patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
 Experimental Arm: Abemaciclib + Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression)
 Control Arm: Standard endocrine therapy

